Grey Wolf Therapeutics completes £2.5 million ($3.3 million) Series A2 financing to accelerate development of therapies targeting ERAP2. Grey Wolf targets ERAP antigen presentation pathways with the aim of 'illuminating' non-responsive tumors for attack and destruction by the immune system.
Leading in vivo pharmacology and consultancy services firm RenaSci, part of the Sygnature Group, have bolstered their Kidney Disease and Fibrosis capabilities with the appointment of Dr Wioletta Pijacka.
TTP Labtech Ltd, a global leader in the design and development of automated instrumentation and consumables for life science applications, has announced its corporate name change to SPT Labtech effective from January 6, 2020.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, today announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range.